Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 8/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 2/20 | 0.38 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13131326 | 0.87 | REN (0.46) | RENHTR1BSLC6A4HRH1KDM1A | |
| SCHEMBL2808494 | 0.85 | REN (0.45) | RENHTR1BSLC6A4HRH1KDM1A | |
| SCHEMBL18509049 | 0.83 | REN (0.36) | RENPKMKDM4EALDH1A1 | |
| SCHEMBL27795823 | 0.83 | REN (0.44) | RENHTR1BSLC6A4HRH1KDM1A | |
| SCHEMBL13131958 | 0.82 | KDM4E (0.36) | RENKDM4EALDH1A1HPGD | |
| SCHEMBL1941564 | 0.81 | PKM (0.48) | PKMALDH1A1 | |
| SCHEMBL6042539 | 0.80 | SMN1; SMN2 (0.42) | PKMALDH1A1HPGD | |
| SCHEMBL13131957 | 0.78 | L3MBTL1 (0.36) | RENPKMKDM4EALDH1A1 | |
| SCHEMBL2810309 | 0.78 | REN (0.47) | RENSLC6A4HRH1KDM4EALDH1A1 | |
| SCHEMBL13132193 | 0.77 | MRGPRX4 (0.45) | RENKCNA3KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975252-B2 | Morpholine derivative | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-03-10 | — | — | US | disclosed |
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | REN, AGTR1, AGTR2 | REN 1/4885PKM 780/4885HTR1B 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.